Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab′) 2 uptake in SKBR3 tumor xenografts

Molecular Pharmaceutics

Volumn 9, Issue 11, 2012, Pages 2995-3002

  Oude Munnink, Thijs H ^a   De Vries, Elisabeth G E ^a   Vedelaar, Silke R ^a   Timmer Bosscha, Hetty ^a   Schröder, Carolina P ^a   Brouwers, Adrienne H ^a   Lub De Hooge, Marjolijn N ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

17AAG; HER2; HSP90; lapatinib; PET

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB; ZIRCONIUM DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG DISTRIBUTION; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOQUINONES; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENES, ERBB-1; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN FAB FRAGMENTS; LACTAMS, MACROCYCLIC; MALE; MICE; MICE, INBRED BALB C; QUINAZOLINES; RECEPTOR, ERBB-2; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84868579267     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp3002182     Document Type: Article

References (39)

1. Moasser, M. M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis Oncogene 2007, 26, 6469-6487
2. Hayes, D. F.; Thor, A. D.; Dressler, L. G. HER2 and response to paclitaxel in node-positive breast cancer N. Engl. J. Med. 2007, 357, 1496-1506
3. Baselga, J.; Swain, S. M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 Nat. Rev. Cancer 2009, 9, 463-475
4. Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 1987, 235, 177-182
5. Dahabreh, I. J.; Linardou, H.; Siannis, F.; Fountzilas, G.; Murray, S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials Oncologist 2008, 13, 620-630
6. Dawood, S.; Broglio, K.; Buzdar, A. U.; Hortobagyi, G. N.; Giordano, S. H. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review J. Clin. Oncol. 2010, 28, 92-98
7. www.accessdata.fda.gov/drugsatfda-docs/label/2010/103792s5250lbl.pdf; October 2011.
8. Spector, N. L.; Blackwell, K. L. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer J. Clin. Oncol. 2009, 27, 5838-5847
9. Tagliabue, E.; Balsari, A.; Campiglio, M.; Pupa, S. M. HER2 as a target for breast cancer therapy Expert Opin. Biol. Ther. 2010, 10, 711-724
10. Blackwell, K. L.; Burstein, H. J.; Storniolo, A. M. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer J. Clin. Oncol. 2010, 28, 1124-1130
11. Baselga, J.; Bradbury, I.; Eidtmann, H. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet 2012, 379, 633-640
12. Eccles, S. A.; Massey, A.; Raynaud, F. I. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis Cancer Res. 2008, 68, 2850-2860
13. Jensen, M. R.; Schoepfer, J.; Radimerski, T. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models Breast Cancer Res. 2008, 10, R33
14. Solit, D. B.; Zheng, F. F.; Drobnjak, M. 17-Allylamino-17-demethoxy- geldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts Clin. Cancer Res. 2002, 8, 986-993
15. Zsebik, B.; Citri, A.; Isola, J.; Yarden, Y.; Szollosi, J.; Vereb, G. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1 Immunol. Lett. 2006, 104, 146-155
16. Oude Munnink, T. H.; Korte, M. A.; Nagengast, W. B. (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft Eur. J. Cancer 2010, 46, 678-684
17. Modi, S.; Stopeck, A. T.; Gordon, M. S. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study J. Clin. Oncol. 2007, 25, 5410-5417
18. Scaltriti, M.; Verma, C.; Guzman, M. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity Oncogene 2009, 28, 803-814
19. Vazquez-Martin, A.; Oliveras-Ferraros, C.; Cufí, S.; Barco, S. D.; Martin-Castillo, B.; Menendez, J. A. Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth J. Cell. Physiol. 2011, 226, 52-57
20. 89Zr-trastuzumab for HER2/ neu immunoPET imaging J. Nucl. Med. 2009, 50, 962-969
21. Dijkers, E. C.; Oude Munnink, T. H.; Kosterink, J. G. Biodistribution of (89)Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer Clin. Pharmacol. Ther. 2010, 87, 586-592
22. 89Zr-labeled monoclonal antibodies J. Nucl. Med. 2003, 44, 1271-1281
23. Lindmo, T.; Boven, E.; Cuttitta, F.; Fedorko, J.; Bunn, P. A., Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess J. Immunol. Methods 1984, 72, 77-89
24. Smith-Jones, P. M.; Solit, D. B.; Akhurst, T.; Afroze, F.; Rosen, N.; Larson, S. M. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors Nat. Biotechnol. 2004, 22, 701-706
25. Loening, A. M.; Gambhir, S. S. AMIDE: a free software tool for multimodality medical image analysis Mol. Imaging 2003, 2, 131-137
26. Tang, Y.; Scollard, D.; Chen, P.; Wang, J.; Holloway, C.; Reilly, R. M. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments Nucl. Med. Commun. 2005, 26, 427-432
27. Tang, Y.; Wang, J.; Scollard, D. A. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments Nucl. Med. Biol. 2005, 32, 51-58
28. Lub-de Hooge, M. N.; Kosterink, J. G.; Perik, P. J. Preclinical characterisation of 111In-DTPA-trastuzumab Br. J. Pharmacol. 2004, 143, 99-106
29. Perik, P. J.; Lub-de Hooge, M. N.; Gietema, J. A. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer J. Clin. Oncol. 2006, 24, 2276-2282
30. Sorkin, A.; Goh, L. K. Endocytosis and intracellular trafficking of ErbBs Exp. Cell Res. 2008, 314, 3093-3106
31. Roepstorff, K.; Grovdal, L.; Grandal, M.; Lerdrup, M.; van Deurs, B. Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer Histochem. Cell Biol. 2008, 129, 563-578
32. Austin, C. D.; De Mazière, A. M.; Pisacane, P. I. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin Mol. Biol. Cell 2004, 15, 5268-5282
33. Gilboa, L.; Ben Levy, R.; Yarden, Y.; Henis, Y. I. Roles for a cytoplasmic tyrosine and tyrosine kinase activity in the interactions of Neu receptors with coated pits J. Biol. Chem. 1995, 270, 7061-7067
34. Burris, H. A., 3rd; Rugo, H. S.; Vukelja, S. J. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy J. Clin. Oncol. 2011, 29, 398-405
35. Isakoff, S. J.; Baselga, J. Trastuzumab-DM1: Building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer J. Clin. Oncol. 2011, 29, 351-354
36. Lewis Phillips, G. D.; Fields, C.; Crocker, L. Potent anti-tumor activity of trastuzumab-DM1 antibody-drug conjugate in combination with cytotoxic chemotherapeutic agents, antibodies or small molecule kinase inhibitors AACR Meet. Abstr. 2008, 2133
37. Krop, I. E.; Beeram, M.; Modi, S. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer J. Clin. Oncol. 2010, 28, 2698-2704
38. Lewis Phillips, G. D.; Li, G.; Dugger, D. L. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res. 2008, 68, 9280-9290
39. Leow, C. C.; Chesebrough, J.; Coffman, K. T. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib Mol. Cancer Ther. 2009, 8, 2131-2141